Senexis, Alzhyme collaborate for new Alzheimer’s test
This article was originally published in Clinica
UK drug development firm Senexis has agreed to work with Australian biopharmaceutical company Alzhyme in order to develop a new diagnostic test for the early detection of Alzheimer’s disease. Cambridge, UK-based Senexis said that the new test would be designed for routine detection of disease biomarkers in the blood. “In spite of the attention Alzheimer’s receives, there is a significant medical need for the early detection of the condition,” said Senexis CEO Mark Treherne. The incidence of the disease is widely expected to double over the next two decades – in the US alone, five million people currently suffer from Alzheimer’s. Financial details of the collaboration were not revealed.